Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Avenard

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
New Biotechnology|April 25, 2018
Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical developmentKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Mabs|June 10, 2017
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risksKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 25, 2019
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) FabChristine Voors-Pette, Kristell Lebozec, Peter Dogterom, et al.
Plos One|June 17, 2024
Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trialJulien Pottecher, Francois Raffi, Martine Jandrot-Perrus, et al.
The Lancet. Neurology|January 24, 2024
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trialMikaël Mazighi, Martin Köhrmann, Robin Lemmens, et al.
Stroke|April 27, 2026
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind StudyMartin Köhrmann, Jörg Berrouschot, Joaquín Serena, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
New Biotechnology|April 25, 2018
Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical developmentKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Mabs|June 10, 2017
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risksKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 25, 2019
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) FabChristine Voors-Pette, Kristell Lebozec, Peter Dogterom, et al.
Plos One|June 17, 2024
Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trialJulien Pottecher, Francois Raffi, Martine Jandrot-Perrus, et al.
The Lancet. Neurology|January 24, 2024
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trialMikaël Mazighi, Martin Köhrmann, Robin Lemmens, et al.
Stroke|April 27, 2026
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind StudyMartin Köhrmann, Jörg Berrouschot, Joaquín Serena, et al.
Pageof 1